Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of SBRT plus ipilimumab and nivolumab versus ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
2018-003461-34Phase 2Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Herlev & Gentofte Hospital. Primary endpoint: Coprimary endpoints. Started Mar 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2018-003461-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003461-34.